Back to Search Start Over

Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset.

Authors :
Elkhalifa M
Orbai AM
Magder LS
Petri M
Alarcón GS
Gordon C
Merrill J
Fortin PR
Bruce IN
Isenberg D
Wallace D
Nived O
Ramsey-Goldman R
Bae SC
Hanly JG
Sanchez-Guerrero J
Clarke AE
Aranow C
Manzi S
Urowitz M
Gladman DD
Kalunian K
Werth VP
Zoma A
Bernatsky S
Khamashta M
Jacobsen S
Buyon JP
Dooley MA
Vollenhoven RV
Ginzler E
Stoll T
Peschken C
Jorizzo JL
Callen JP
Lim S
Inanc M
Kamen DL
Rahman A
Steinsson K
Franks AG Jr
Source :
Lupus [Lupus] 2021 Jul; Vol. 30 (8), pp. 1283-1288. Date of Electronic Publication: 2021 May 06.
Publication Year :
2021

Abstract

Objective: Anti-beta 2 glycoprotein I IgA is a common isotype of anti-beta 2 glycoprotein I in SLE. Anti-beta 2 glycoprotein I was not included in the American College of Rheumatology (ACR) SLE classification criteria, but was included in the Systemic Lupus International Collaborating Clinics (SLICC) criteria. We aimed to evaluate the prevalence of anti-beta 2-glycoprotein I IgA in SLE versus other rheumatic diseases. In addition, we examined the association between anti-beta 2 glycoprotein I IgA and disease manifestations in SLE.<br />Methods: The dataset consisted of 1384 patients, 657 with a consensus physician diagnosis of SLE and 727 controls with other rheumatic diseases. Anti-beta 2 glycoprotein I isotypes were measured by ELISA. Patients with a consensus diagnosis of SLE were compared to controls with respect to presence of anti-beta 2 glycoprotein I. Among patients with SLE, we assessed the association between anti-beta 2 glycoprotein I IgA and clinical manifestations.<br />Results: The prevalence of anti-beta 2 glycoprotein I IgA was 14% in SLE patients and 7% in rheumatic disease controls (odds ratio, OR 2.3, 95% CI: 1.6, 3.3). It was more common in SLE patients who were younger patients and of African descent (p = 0.019). Eleven percent of SLE patients had anti-beta 2 glycoprotein I IgA alone (no anti-beta 2 glycoprotein I IgG or IgM). There was a significant association between anti-beta 2 glycoprotein I IgA and anti-dsDNA (p = 0.001) and the other antiphospholipid antibodies (p = 0.0004). There was no significant correlation of anti-beta 2 glycoprotein I IgA with any of the other ACR or SLICC clinical criteria for SLE. Those with anti-beta 2 glycoprotein I IgA tended to have a history of thrombosis (12% vs 6%, p = 0.071), but the difference was not statistically significant.<br />Conclusion: We found the anti-beta 2 glycoprotein I IgA isotype to be more common in patients with SLE and in particular, with African descent. It could occur alone without other isotypes.

Details

Language :
English
ISSN :
1477-0962
Volume :
30
Issue :
8
Database :
MEDLINE
Journal :
Lupus
Publication Type :
Academic Journal
Accession number :
33957797
Full Text :
https://doi.org/10.1177/09612033211014248